BSTC - バイオスペシフィックス・テクノロジ―ズ (BioSpecifics Technologies Corp) バイオスペシフィックス・テクノロジ―ズ

 BSTCのチャート


 BSTCの企業情報

symbol BSTC
会社名 Biospecifics Technologies Corp. (バイオスペシフィックス・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイオスペシフィクス・テクノロジーズ(BioSpecifics Technologies Corp.)は多種の適応症向けの注射コラゲナーゼの開発に従事するバイオ製薬会社である。同社はバミューダの無限責任会社Endo Global Venturesと開発中と市販の注射コラゲナーゼの開発及びライセンス契約を締結した。クロストリジウムヒストリチカムの注射可能なコラゲナーゼはXIAFLEX(ヨーロッパで)として販売される。ペイロニー病、デュピュイトラン拘縮の適応症向けの二つの注射コラゲナーゼが市販される。ケロイド、肥厚性瘢痕、瘢痕腱、緑内障、ヘルニア化椎間板等の適応症向けの、そして硝子体切除術の補助として他の臨床的な注射コラゲナーゼは試験された。同社はコラゲナーゼを利用可能な適応症の追加開発を評価する中である。   バイオスペシフィックス・テクノロジ―ズは米国のバイオ医薬品会社。「シアフレックス」の名前でデュピュイトラン拘縮とペイロニ―病治療用のコグラナ―ゼ・ヒストリチクム菌注射剤を開発、製造。また、肩関節周囲炎、セルライト、脂肪腫(人・犬)の治療用のコグラナ―ゼ注射剤を開発、研究中。   
本社所在地 35 Wilbur Street Lynbrook NY 11563 USA
代表者氏名 Thomas L. Wegman トーマス・L・ウェグマン
代表者役職名 President Principal Executive Officer Principal Financial Officer Director
電話番号 +1 516-593-7000
設立年月日 33178
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 5人
url www.biospecifics.com
nasdaq_url https://www.nasdaq.com/symbol/bstc
adr_tso
EBITDA EBITDA(百万ドル) 21.03364
終値(lastsale) 59.74
時価総額(marketcap) 435796609.12
時価総額 時価総額(百万ドル) 434.11880
売上高 売上高(百万ドル) 27.40344
企業価値(EV) 企業価値(EV)(百万ドル) 367.57240
当期純利益 当期純利益(百万ドル) 14.73869
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioSpecifics Technologies Corp. revenues remained flat at $14.2M. Net income increased 39% to $8.3M. Revenues reflect Licensing revenue increase from $9K to $40K. Net income benefited from General and administrative decrease of 15% to $4M (expense) Interest income increase from $243K to $492K (income) Research and development decrease of 31% to $407K (expense).

 BSTCのテクニカル分析


 BSTCのニュース

   BioSpecifics Reports Third Quarter 2020 Financial and Operating Results  2020/11/09 13:00:00 PR Newswire
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.  2020/11/04 00:41:00 PR Newswire
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. ("BSTC" or the "Company") (NASDAQ: BSTC) in connection with the proposed acquisition of the…
   Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.  2020/11/02 12:00:00 PR Newswire
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common…
   BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC  2020/10/26 19:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the pr
   HC Wainwright Downgrades BioSpecifics Technologies (NASDAQ:BSTC) to Neutral  2020/10/22 04:56:51 Stock Observer
BioSpecifics Technologies (NASDAQ:BSTC) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, AnalystRatings.net reports. They currently have a $88.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $100.00. HC Wainwright’s target price points to […]
   BioSpecifics Reports Third Quarter 2020 Financial and Operating Results  2020/11/09 13:00:00 PR Newswire
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.  2020/11/04 00:41:00 PR Newswire
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. ("BSTC" or the "Company") (NASDAQ: BSTC) in connection with the proposed acquisition of the…
   Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.  2020/11/02 12:00:00 PR Newswire
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common…
   BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC  2020/10/26 19:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the pr
   HC Wainwright Downgrades BioSpecifics Technologies (NASDAQ:BSTC) to Neutral  2020/10/22 04:56:51 Stock Observer
BioSpecifics Technologies (NASDAQ:BSTC) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, AnalystRatings.net reports. They currently have a $88.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $100.00. HC Wainwright’s target price points to […]
   BioSpecifics Reports Third Quarter 2020 Financial and Operating Results  2020/11/09 13:00:00 PR Newswire
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.  2020/11/04 00:41:00 PR Newswire
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. ("BSTC" or the "Company") (NASDAQ: BSTC) in connection with the proposed acquisition of the…
   Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.  2020/11/02 12:00:00 PR Newswire
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common…
   BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC  2020/10/26 19:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the pr
   HC Wainwright Downgrades BioSpecifics Technologies (NASDAQ:BSTC) to Neutral  2020/10/22 04:56:51 Stock Observer
BioSpecifics Technologies (NASDAQ:BSTC) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, AnalystRatings.net reports. They currently have a $88.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $100.00. HC Wainwright’s target price points to […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイオスペシフィックス・テクノロジ―ズ BSTC BioSpecifics Technologies Corp)

 twitter  (公式ツイッターやCEOツイッターなど)